GERD Re-Treatment Should Be Assessed In Enteryx Postmarket Study – Panel
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's Enteryx is approvable for gastroesophageal reflux disease, contingent on a placebo-controlled, postmarket study, FDA's Gastroenterology & Urology Devices Panel concluded Jan. 17 in Gaithersburg, Md